"We are currently developing antibodies that can be given to patients with coronavirus in the form of a medicine," RIA Novosti quoted Gintsburg as saying.
According to him, clinical trials of this drug will begin in January 2022 and will be completed within three to four months.
Earlier, an infectious disease doctor, associate professor of the Department of Infectious Diseases with courses in epidemiology and phthisiology at the Peoples' Friendship University of Russia, the Ministry of Education and Science, Sergei Voznesensky, in an interview with 360, pointed out the complexity of mass testing of antibodies to COVID-19 in Russians.